Molecular Diagnostics Market Report
Covid-19 has impacted the market dynamics, competition, and global supply chains. The revenues has gone down in 2020 and may resume an uptrend gradually form 2021. Companies optimizing their operation and statergy will sustain and beat the competition.
Note: The summary below might not have included insights on covid impact since we have large number of reports.
This report, from Stratview Research, studies the molecular diagnostics market over the trend period of 2014 to 2017 and forecast period of 2018 to 2025. The report provides detailed insights into the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.
The Burning Questions This Report Will Answer:
Why clinical molecular diagnostics is gaining clinical importance? Compared with conventional culture-based techniques, molecular diagnostic approaches provide substantially more rapid and specific information on organism identification and on the presence of resistance mechanisms. Such method enhances antimicrobial stewardship and decreases ‘time to appropriate antibiotics’, one of the most important factors in improving the prognosis of patients with life-threatening infections and improves DALY.
Molecular diagnostics of infectious diseases especially nucleic-acid-based processes, are the fastest growing field in clinical laboratory diagnostics. It involves stepwise replacing or complementing culture-based, biochemical, and immunological assays in microbiology laboratories. The first-generation nucleic acid assays were mono-parametric such as conventional tests, determining only a single parameter. With the introduction of advanced technologies such as microarrays, multiplex nucleic acid amplification techniques, or mass spectrometry, have actually reduced contamination risk while increasing the turnaround time (TAT) of results.
Danaher Corporation (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), Becton, Dickinson and Company and Biomérieux SA and few others are leading the global clinical microbiology market.
Our reports offer high-quality insights and are the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. About 10 detailed primary interviews with the market players across the value chain in all four regions and industry experts have been executed to obtain both the qualitative and quantitative insights.
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:
The global molecular diagnostics market is segmented into the following categories:
By Product & Service
By Testing Facility
With this detailed report, Stratview Research offers one of the following free customization options to our first-time clients:
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].